Shruthi H. Iyer

Shruthi H. Iyer

Auto-generated profile, based on publicly available information

Shruthi H. Iyer

Department of Pharmacology & Neuroscience, Creighton University School of Medicine, Omaha, NE 68178, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2018 in Epilepsia
Verified
Journal Article
Closed access
PDF file
KSKristina A. Simeone
Kristina A. Simeone
JHJodi Hallgren
Jodi Hallgren
CBCharles S. Bockman
Charles S. Bockman
AAAnkita Aggarwal
Ankita Aggarwal
Vikash KansalVikash Kansal
Vikash Kansal
TSTimothy A. Simeone
Timothy A. Simeone

28 November 2017 in Epilepsia
Verified
Journal Article
Closed access
PDF file
SIShruthi H. Iyer
Shruthi H. Iyer
SMStephanie A. Matthews
Stephanie A. Matthews
TSTimothy A. Simeone
Timothy A. Simeone
RMRama Maganti
Rama Maganti
KSKristina A. Simeone
Kristina A. Simeone

17 February 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
SIShruthi H. Iyer
Shruthi H. Iyer
Mary Elizabeth YehMary Elizabeth Yeh
Mary Elizabeth Yeh
LNLauren Netzel
Lauren Netzel
MLMolly G. Lindsey
Molly G. Lindsey
MWMcKenzie Wallace
McKenzie Wallace
Timothy A. SimeoneTimothy A. Simeone
Timothy A. Simeone
Epilepsy often occurs with other neurological disorders, such as autism, affective disorders, and cognitive impairment. Research indicates that many neurological disorders share a common pathophysiology of dysfunctional energy metabolism, neuroinflammation, oxidative stress, and gut dysbiosis. The past decade has witnessed a growing interest in the use of metabolic therapies for these disorders with or without the context of epilepsy. Over one hundred years ago, the high-fat, low-carbohydrate ketogenic diet (KD) was formulated as a treatment for epilepsy. For those who cannot tolerate the KD, other diets have been developed to provide similar seizure control, presumably through similar mechanisms. These include, but are not limited to, the medium-chain triglyceride diet, low glycemic index diet, and calorie restriction. In addition, dietary supplementation with ketone bodies, polyunsaturated fatty acids, or triheptanoin may also be beneficial. The proposed mechanisms through which these diets and supplements work to reduce neuronal hyperexcitability involve normalization of aberrant energy metabolism, dampening of inflammation, promotion of endogenous antioxidants, and reduction of gut dysbiosis. This raises the possibility that these dietary and metabolic therapies may not only exert anti-seizure effects, but also reduce comorbid disorders in people with epilepsy. Here, we explore this possibility and review the clinical and preclinical evidence where available.

9 September 2025 in Epilepsia
Verified
Journal Article
Closed access
SIShruthi H. Iyer
Shruthi H. Iyer
JHJillian E. Hinman
Jillian E. Hinman
SDSamantha B. Draves
Samantha B. Draves
SMStephanie A. Matthews
Stephanie A. Matthews
KSKristina A. Simeone
Kristina A. Simeone
Timothy A. SimeoneTimothy A. Simeone
Timothy A. Simeone

28 May 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
PRParisa Rafiei
Parisa Rafiei
HMHuda Saadia Mian
Huda Saadia Mian
SIShruthi H. Iyer
Shruthi H. Iyer
Samantha Brittany DravesSamantha Brittany Draves
Samantha Brittany Draves
SMStephanie A. Matthews
Stephanie A. Matthews
KSKristina A. Simeone
Kristina A. Simeone
Background/Objectives: Hyperexcitable neuronal activity associated with seizures may disrupt brain homeostasis resulting in abnormal glucose and nutrient management and metabolism. Specialized ependymal cells known as tanycytes line the third ventricle wall bridging communication between the brain, CSF, and blood. Despite their positional importance, whether tanycytes are impacted by epilepsy is unknown. Here, known protein markers of tanycytes were assessed in the Kcna1-null mouse model of genetic epilepsy with spontaneous recurrent seizures (SRS mice). Further, whether an anti-seizure metabolic ketogenic diet (KD), previously proven effective in SRS mice, restored protein levels was determined. Methods: Known tanycyte proteins, including glucose transporter 1 (GLUT1), glial fibrillary acidic protein (GFAP), and doublecortin (DCX, to determine potential neurogenic differences) were examined throughout the anterior–posterior axis of the third ventricle using immunofluorescent histochemistry. Results: Decreased GLUT1 immunoreactivity and elevated GFAP levels were found in the SRS cohorts. The number of neurogenic DCX-expressing cells did not differ. Two weeks of KD treatment reduced GFAP to WT levels. GLUT1 remained low in KD-treated SRS mice. Conclusions: These data suggest that the expression of proteins important for the structure and function of tanycytes is altered in preclinical epilepsy and is differentially restored with KD treatment. Whether tanycytes actively participate in the pathophysiology of epilepsy or associated comorbidities is an intriguing possibility given their integral role in brain homeostasis.

18 February 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
SHSegewkal Hawaze Heruye
Segewkal Hawaze Heruye
SMStephanie A. Matthews
Stephanie A. Matthews
SIShruthi H. Iyer
Shruthi H. Iyer
MDMalavika Deodhar
Malavika Deodhar
TWTed J. Warren
Ted J. Warren
Timothy A. SimeoneTimothy A. Simeone
Timothy A. Simeone
Cognitive impairment is a major comorbidity in temporal lobe epilepsy (TLE), yet its underlying pathophysiology remains poorly understood and current therapies provide minimal benefit. While oxidative stress has traditionally been viewed as a precursor to cell death-mediated cognitive decline, cell death is absent in many patients and preclinical models with memory impairment. Here, we tested whether excessive mitochondrial reactive oxygen species (ROS) actively contribute to memory impairment through mechanisms distinct from cell death. Using Kv1.1 knockout (KO) mice, a TLE model with mitochondrial respiratory chain complex I (MRCI) impairment, we found elevated hippocampal mitochondrial superoxide, impaired recognition memory, deficits in synaptic plasticity, and abnormal sharp wave–ripple oscillations. Applying the MRCI inhibitor rotenone to wild-type hippocampal slices caused increased superoxide and mirrored electrophysiology deficits. Both acute and sub-chronic treatment with the mitochondria-targeted antioxidant mitoquinone (MitoQ) reduced superoxide levels, rescued synaptic plasticity, restored network activity, and normalized memory performance in KO mice—without altering seizure frequency, severity, or neuronal excitability. Our results identify mitochondrial superoxide as a reversible driver of hippocampal dysfunction in epilepsy and demonstrate that mitochondria-targeted antioxidant therapy can restore cognition despite persistent seizures. This study provides proof-of-concept for novel treatments improving cognitive comorbidities in TLE beyond seizure control.